Unmasking
Cancer Cell
Camouflage

Unmasking
Cancer Cell
Camouflage
KAHR develops innovative immuno-recruitment cancer drugs
that activate immune responses by converting cancer camouflage
into beacons for the immune system to attack

Synergistic recruitment and activation of innate
and adaptive anti-cancer immunity

with Multifunctional Immuno-Recruitment Proteins (MIRP)

SIRPα

  • Binds CD47 on tumor cells
  • Prevents “don’t eat me” signals
  • Phagocytes ingest tumor cells

41BBL

  • Binds 41BB receptor on T cells
  • T-cell activation and proliferation
  • T-cell induced tumor killing

Unique Features

Synergistic effect of
innate and adaptive
anticancer immunity

Trimeric structures for increased
specificity and optimal immune
cell activation

Conditional and
tumor-localized immune
cell recruitment

Differentiated PK/PD
relationships for wider
therapeutic window

Potential for solid
and hematological
malignancies

Contact Us

KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com